German firm Boehringer Ingelheim’s patent for asthma drug revoked
India's Patent Office has revoked a patent on asthma drug, Spiriva held by German major Boehringer Ingelheim on an opposition filed by generic company, Cipla. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 10, 2015 Category: Pharmaceuticals Source Type: news

Boehringer Ingelheim reveals new Phase III data on Tiotropium in asthma patients
Boehringer Ingelheim has revealed new Phase III data on tiotropium, which showed that the drug candidate improves lung function in adult patients with mild, moderate and severe asthma irrespective of allergic status. (Source: Drug Development Technology)
Source: Drug Development Technology - February 23, 2015 Category: Pharmaceuticals Source Type: news

Tiotropium Showing Promise in Pediatric AsthmaTiotropium Showing Promise in Pediatric Asthma
A drug and device combination already approved for COPD and effective in adults with asthma could provide an option for children with refractory disease. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 31, 2014 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

Theravance reports positive data from Anoro Ellipta’s third lung function trial in COPD
Theravance has reported positive results from a third lung function trial of Anoro Ellipta (umeclidinium /vilanterol, UMEC/VI) with the LAMA tiotropium, administered in the HandiHaler inhaler, in patients with chronic obstructive pulmonary disease (C… (Source: Drug Development Technology)
Source: Drug Development Technology - October 21, 2014 Category: Pharmaceuticals Source Type: news

Spiriva Respimat (Tiotropium Bromide Inhalation Spray) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 6, 2014 Category: Drugs & Pharmacology Source Type: news

FDA OKs Mist Spray Form of Tiotropium (Spiriva Respimat)FDA OKs Mist Spray Form of Tiotropium (Spiriva Respimat)
It's easier to use than the inhalation powder version called Spiriva HandiHaler, according to the manufacturer. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 26, 2014 Category: Consumer Health News Tags: Pulmonary Medicine News Alert Source Type: news

FDA OKs Spiriva Respimat for COPD
(MedPage Today) -- Approval of mist formulation follows support from advisory panel. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - September 25, 2014 Category: Primary Care Source Type: news

Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to...
LifeScienceIndustryResearch.com adds “Spiriva (Asthma) – Forecast and Market Analysis to 2023” to its store. Detailed information on Spiriva including product description, safety and efficacy...(PRWeb September 21, 2014)Read the full story at http://www.prweb.com/releases/spiriva-asthma-market/forecast-analysis-to-2023/prweb12184513.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 21, 2014 Category: Pharmaceuticals Source Type: news

Boehringer reports positive results from Phase III trials of COPD combination drug
Boehringer Ingelheim Pharmaceuticals has reported data from the pivotal Phase III TONADO I and II trials (NCT01431274/NCT01431287) for the fixed-dose combination (FDC) of tiotropium, plus olodaterol to treat patients with moderate to very severe chr… (Source: Drug Development Technology)
Source: Drug Development Technology - September 9, 2014 Category: Pharmaceuticals Source Type: news

TONADO™ study shows further benefits in COPD
Data from the pivotal Phase III TONADO™ studies for tiotropium + olodaterol Respimat® fixed dose combination (FDC) were presented for the first time at the European Respiratory Society (ERS) International Congress 2014 in Munich. (Source: Pharmacy Europe)
Source: Pharmacy Europe - September 8, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Industry News Respiratory copd fixed dose combination Latest News phase iii trial tiotropium olodaterol Source Type: news

Tiotropium in the Treatment of Patients With AsthmaTiotropium in the Treatment of Patients With Asthma
Tiotropium, a long-acting anticholinergic agent used in patients with COPD, is showing encouraging results as an alternative treatment in patients with asthma. Southern Medical Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 5, 2014 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news

Respimat® fixed-dose combination in COPD
Boehringer Ingelheim has announced the submission of Marketing Authorisation Applications in 31 European countries for the once-daily fixed-dose combination of tiotropium + olodaterol Respimat®. (Source: Pharmacy Europe)
Source: Pharmacy Europe - July 3, 2014 Category: Drugs & Pharmacology Authors: AMcculloch Tags: *** Editor's Pick Respiratory boehringer ingelheim chronic obstructive pulmonary disease copd Latest News Respimat tiotropium olodaterol Source Type: news

Umeclidinium Plus Vilanterol Helpful in COPDUmeclidinium Plus Vilanterol Helpful in COPD
In patients with COPD, umeclidinium plus vilanterol can boost lung function to a greater extent than either drug alone or the globally approved agent tiotropium, researchers report. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 5, 2014 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

Buy Spiriva Online From Adv-Care Pharmacy
Adv-Care Pharmacy announces the online availability of Spiriva(PRWeb March 10, 2014)Read the full story at http://www.prweb.com/releases/2014/03/prweb11656137.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 11, 2014 Category: Pharmaceuticals Source Type: news

Tiotropium Complements Steroids in Treatment of AsthmaTiotropium Complements Steroids in Treatment of Asthma
The long-acting anticholinergic bronchodilator and selective M3 muscarinic-receptor agonist may help patients whose asthma is not completely controlled with current therapies. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 6, 2014 Category: Consumer Health News Tags: Allergy & Clinical Immunology News Source Type: news

Spiriva Cuts Flares in Heavily Treated Asthma
SAN DIEGO (MedPage Today) -- Tiotropium (Spiriva) Respimat improved lung function and cut exacerbations in severe asthma patients who had already maxed out other treatment options, pooled analysis of two phase III trials showed. (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - March 4, 2014 Category: Pediatrics Source Type: news

New Phase III data demonstrate tiotropium Respimat® improves lung function versus placebo and is well tolerated in asthma patients
Boehringer Ingelheim has announced new data from large scale, Phase III studies showing that once-daily tiotropium delivered via the Respimat® Soft Mist™ Inhaler improved lung function and was well tolerated in patients with varying degrees of asthma severity.1 These data were presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2014 annual meeting in San Diego. The first results from the Phase III GraziaTinA-asthma® study demonstrated that tiotropium Respimat® 5 mcg and 2. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 4, 2014 Category: Consumer Health News Tags: Respiratory / Asthma Source Type: news

Boehringer releases positive Phase III trial results of tiotropium Respimat in asthma patients
Boehringer Ingelheim has reported positive results from large-scale Phase III studies demonstrating that once-daily tiotropium delivered via the Respimat inhaler was effective and well-tolerated in patients across asthma severities. (Source: Drug Development Technology)
Source: Drug Development Technology - March 4, 2014 Category: Pharmaceuticals Source Type: news

Minor added benefit of indacaterol/glycopyrronium in COPD
Adults with COPD of moderate or severe severity grade with no more than 2 flare-ups per year have fewer breathing difficulties when treated with the drug combination. According to the findings, the drug combination is better at relieving breathing difficulties (dyspnoea) than a combination treatment with tiotropium and formoterol. However, this only applies to patients who do not yet need inhaled corticosteroids because they have no more than 2 acute flare-ups (exacerbations) per year. Furthermore, there is an indication that the severity of the disease may influence the treatment result, and hence is a so-called "eff...
Source: ScienceDaily Headlines - February 19, 2014 Category: Science Source Type: news

Pulmonology Top News: Spiriva Signal, LABA Risk
(MedPage Today) -- A heart attack signal with tiotropium (Spiriva) and a potential genetic explanation for severe adverse events with long-acting beta agonists (LABAs) in asthma topped the news in pulmonology this week. (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - January 31, 2014 Category: Allergy & Immunology Source Type: news

Heart Attack Signal Found for Spiriva in COPD
(MedPage Today) -- The TIOSPIR trial was used to support safety of the mist inhaler version of tiotropium (Spiriva) compared with dry powder, but the pooled data actually showed something else -- a heart attack signal, researchers argued. (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - January 29, 2014 Category: Allergy & Immunology Source Type: news

Week Ahead in Pulmonology: New Allergy Tx? Spiriva Safety
(MedPage Today) -- Is a new ragweed allergy treatment likely to get the FDA green light? Look for that pulmonology news this week, along with more controversy over the link between the tiotropium mist inhaler (Spiriva) and deaths in COPD. (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - January 27, 2014 Category: Allergy & Immunology Source Type: news

COPD and Safety of Tiotropium: Disproving a Negative?COPD and Safety of Tiotropium: Disproving a Negative?
The authors of a new study seek to determine the safety and efficacy of different formulations of tiotropium as a COPD therapy. Medscape Pulmonary Medicine (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - January 6, 2014 Category: Internal Medicine Tags: Pulmonary Medicine Commentary Source Type: news

Featured in NEJM Journal Watch: Tiotropium Benefits Some Patients Who Don't Respond to Beta-Agonists (FREE)
By the NEJM Journal Watch Editors In a study … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - December 3, 2013 Category: Primary Care Source Type: news

Boehringer seeks European approval for expanded indication of tiotropium Respimat
German pharmaceutical firm Boehringer Ingelheim has submitted European marketing authorisation (MA) applications to extend the indication to use tiotropium (Spiriva) Respimat for the treatment of asthma in adults aged 18 years and over. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - November 15, 2013 Category: Pharmaceuticals Source Type: news

Tiotropium Safety: Powder vs Soft Mist Formula for COPDTiotropium Safety: Powder vs Soft Mist Formula for COPD
How does the soft mist formulation of tiotropium stack up against the powder formula in terms of safety and efficacy for COPD? Medscape Pulmonary Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 7, 2013 Category: Consumer Health News Tags: Pulmonary Medicine Viewpoint Source Type: news

Indacaterol and Tiotropium Similar in Effect and SafetyIndacaterol and Tiotropium Similar in Effect and Safety
Indacaterol and tiotropium are 'equally effective' in patients with severe chronic obstructive pulmonary disease and a history of serious exacerbations, new data show. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 30, 2013 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

Tiotropium Respimat as Safe as HandiHalerTiotropium Respimat as Safe as HandiHaler
A study of 17,000 COPD patients settles it: mortality rates with tiotropium Respimat and tiotropium HandiHaler are equivalent. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 18, 2013 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

Safety and efficacy profile of Spiriva® Respimat® in the treatment of COPD
TIOSPIR™ (Tiotropium Safety and Performance in Respimat), with over 17,000 COPD patients included, was one of the largest international COPD trials ever conducted, confirmed the comparable mortality and exacerbation efficacy profile of Spiriva® Respimat® 5mcg and Spiriva® HandiHaler® 18mug.(1) (Source: Pharmacy Europe)
Source: Pharmacy Europe - September 12, 2013 Category: Drugs & Pharmacology Authors: ebercott Tags: *** Editor's Pick Respiratory Latest News Source Type: news

Conflicting Data on Spiriva Safety (CME/CE)
BARCELONA (MedPage Today) -- Real-world data indicating excess mortality with the mist version of tiotropium (Spiriva) was countered by further details from the TIOSPIR trial indicating no difference versus the dry powder version, which many here declared the winner in the data duel. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 11, 2013 Category: Cardiology Source Type: news

Study Reassures on Safety of Inhaled TiotropiumStudy Reassures on Safety of Inhaled Tiotropium
A major study on the safety of Boehringer Ingelheim's mist inhaler Spiriva (tiotropium) for chronic lung disease has found it does not increase the risk of early death, in contrast to an earlier analysis published two years ago. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 9, 2013 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

Large International Study of COPD Drug Finds Two Types of Inhalers Equally Safe and Effective - 9/9/13
An international study led by a Johns Hopkins pulmonary expert finds that the drug tiotropium, marketed as the Spiriva brand, can be delivered safely and effectively to people with chronic obstructive pulmonary disease - COPD - in both mist and traditional dry powder inhalers. (Source: Johns Hopkins Medicine News)
Source: Johns Hopkins Medicine News - September 9, 2013 Category: Research Source Type: news

Large international study of COPD drug finds 2 types of inhalers equally safe and effective
(Johns Hopkins Medicine) An international study led by a Johns Hopkins pulmonary expert finds that the drug tiotropium (marketed as the Spiriva brand), can be delivered safely and effectively to people with chronic obstructive pulmonary disease in both "mist" and traditional "dry powder" inhalers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 8, 2013 Category: Global & Universal Source Type: news

Spiriva Mist Equals Powder for Mortality
BARCELONA (MedPage Today) -- The mist version of tiotropium (Spiriva) was as safe as the dry powder formulation in terms of mortality and cardiovascular events in chronic obstructive pulmonary disease, the TIOSPIR trial showed. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - August 31, 2013 Category: Primary Care Source Type: news

Eklira® Genuair® Provides Significant Improvements In COPD Symptoms Vs Placebo In A 6-Week Study
New Phase IIIb data published in the journal COPD demonstrates comparable efficacy for twice-daily Eklira® Genuair® (aclidinium) vs tiotropium following the 6-week study1. The data show significant improvements in 24-hour bronchodilation for aclidinium vs placebo from day 1 of treatment1. Significant improvements in bronchodilation vs tiotropium were found on day 1 with comparable bronchodilation vs tiotropium at week 61... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 12, 2013 Category: Consumer Health News Tags: COPD Source Type: news

Tiotropium in symptomatic asthma patients
Tiotropium delivered by the Respimat Soft Mist Inhaler increases time to first severe exacerbation (p=0.03) and first episode of asthma worsening (p (Source: Pharmacy Europe)
Source: Pharmacy Europe - May 21, 2013 Category: Drugs & Pharmacology Source Type: news

Novartis once-daily QVA149 in reducing exacerbations in COPD
Results from the 64-week SPARK study published today in Lancet Respiratory Medicine showed that investigational once-daily dual bronchodilator QVA149 (indacaterol maleate 110mcg/glycopyrronium 50mcg) was more effective at reducing all chronic obstructive pulmonary disease (COPD) exacerbations compared to glycopyrronium 50mcg and open-label (OL) tiotropium 18 mcg[1] a treatment with established efficacy in preventing exacerbations.[2–5] This is the first study to evaluate the effect on exacerbations of dual bronchodilation with a fixed-dose combination of a long-acting beta2-agonist (LABA) and a long-acting muscarinic...
Source: Pharmacy Europe - April 24, 2013 Category: Drugs & Pharmacology Source Type: news

More Evidence Tiotropium Soft Mist Inhaler Raises Risk of DeathMore Evidence Tiotropium Soft Mist Inhaler Raises Risk of Death
Dutch researchers found a nearly 30% increased risk of death in patients using tiotropium Respimat soft mist inhaler compared with those using tiotropium dry powder inhaler. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 4, 2013 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

Phase III Results: Tiotropium Respimat® Is Effective In Symptomatic Asthma Patients Irrespective Of Their Allergic Status
New Phase III data presented for the first time at the 2013 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting Tiotropium delivered once daily via Respimat™ significantly improved lung function and reduced asthma exacerbations in patients who remain symptomatic despite treatment with at least ICS[1]/LABA[2], irrespective of their allergic status... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 26, 2013 Category: Consumer Health News Tags: Respiratory / Asthma Source Type: news

Possible alternate therapy for adults with poorly controlled asthma
Tiotropium bromide effective when added to low-dose inhaled corticosteroids (Source: BWH News)
Source: BWH News - September 19, 2010 Category: Hospital Management Source Type: news